Die Resultate aller therapeutischen Bemühungen beim Osophaguskarzinom sind quoad vitam unbefriedigend. Mit der alleinigen Radiotherapie werden bei kurativer Intention 5-Jahres-Überlebensraten von 10% und weniger erreicht bei allerdings negativ selektioniertem Krankengut. Akzeptabel sind hingegen die Palliativergebnisse. Die Ansprechraten liegen zwischen 60 und 80%, die mittlere Remissionsdauer beträgt 3 bis 9 Monate. Bei einem Drittel der Patienten läβt sich eine beschwerdefreie Nahrungspassage für die gesamte Dauer der Erkrankung erreichen. Trotz der notwendigen hohen Dosis von 50 bis 70 Gy sind therapieassoziierte Morbidität und Letalität gering. Gründe für die niedrige Nebenwirkungs- und Komplikationsrate sind eine subtile rechnergestützte Bestrahlungsplanung auf CT-Basis sowie der Einsatz moderner Megavoltbestrahlungsgeräte.

Keywords:
Osophaguskarzinom, Strahlentherapie
This content is only available via PDF.
© 1992 S. Karger AG, Basel
1992
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.